Mark Bodenrader - 06 Feb 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Officer
Signature
/s/ Mark Bodenrader
Issuer symbol
N/A
Transactions as of
06 Feb 2023
Net transactions value
$0
Form type
4
Filing time
08 Feb 2023, 19:26:27 UTC
Previous filing
03 Jun 2022
Next filing
05 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +20,012 $0.000000 20,012 06 Feb 2023 Common Stock 20,012 $34.41 Direct F1
transaction CERE Restricted Stock Units Award $0 +5,085 $0.000000 5,085 06 Feb 2023 Common Stock 5,085 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney. Officer title: Interim Chief Financial Officer, Senior Vice President, Finance and Chief Accounting Officer